ResMed Logo

SDB and positive airway pressure

Untreated OSA has been linked with a number of cardiovascular complications, including hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmias, stroke, and even death.1 In addition to cardiovascular morbidity and mortality, untreated OSA is associated with multiple other negative effects, including excessive daytime sleepiness, reduced cognitive function (e.g. alertness, motor function, recall ability) and poor quality of life.2

CPAP was first described by Professor Colin Sullivan in 1981. Professor Sullivan treated five severe OSA patients with CPAP applied to the nares via tubing and a mask. The CPAP acts as a pneumatic splint which prevents the airway collapsing during sleep. It is considered a safe, non-invasive, highly effective treatment for OSA.3

Continuous positive airway pressure (CPAP) is now widely used and known as the gold standard treatment for OSA. It has been shown to reduce the risk of cardiovascular fatal and non-fatal events and decrease mortality rates compared with untreated OSA4-6. In adherent patients, CPAP therapy has also been shown to significantly improve the symptoms associated with OSA, such as excessive daytime sleepiness, cognitive function and reduced quality of life. 7,8

More Articles

AutoSet technology
Learn more about the differences between fixed pressure and auto-adjusting therapy devices
Diabetes
Explore research about diabetes in relation to sleep and respiratory care.
Mandibular repositioning devices
Mandibular Repositioning Devices are often used as an alternative treatment for Obstructive Sleep Apnoea (OSA). Learn about ResMed’s Narval CCTM, a premier and personalised oral therapy device.